Table 6—

Individual single nucleotide polymorphism(SNP) associations in the studies of longitudinal change of forced expiratory volume in one second (FEV1) and cross-sectional level of FEV1

SNPGenotypeLongitudinal change study#Cross-sectional study
Rapid declinersNondeclinersLow functionHigh functionCodominant modelAdditive model
Unadjusted p-valueAdjusted p-valueUnadjusted p-valueAdjusted p-value
CSF2 -1440AA+100 (35.7)101 (33.0)166 (32.2)180 (34.2)
AG124 (44.3)152 (49.7)252 (48.9)259 (49.2)nsnsnsns
GG56 (20.0)53 (17.3)97 (18.8)88 (17.7)
CSF2 1622CC+194 (69.3)210 (68.6)353 (68.2)340 (64.4)
CT74 (26.4)83 (27.1)140 (27.0)171 (32.4)0.092nsnsns
TT12 (4.3)13 (4.2)25 (4.8)17 (3.2)
CSF3 -1719CC+199 (71.1)214 (70.2)388 (74.3)364 (69.2)
CT71 (25.4)78 (25.6)124 (23.8)147 (28.0)ns0.0590.0540.018
TT10 (3.6)13 (4.3)10 (1.9)15 (2.9)
CSF3 -882GG+117 (41.8)112 (36.7)202 (39.1)224 (43.2)
GA124 (44.3)155 (50.8)234 (45.3)233 (45.0)nsns0.0590.092
AA39 (13.9)38 (12.5)81 (15.7)61 (11.8)
CSF3 2176CC+97 (35.4)105 (34.8)192 (36.8)185 (35.3)
CT130 (47.4)160 (53.0)247 (47.3)259 (49.3)nsnsnsns
TT47 (17.2)37 (12.3)83 (15.9)80 (15.3)
  • Data are presented as n (%). CSF: colony-stimulating factor; ns: nonsignificant. #: unadjusted p-values and p-values adjusted for age, sex, smoking pack-yrs and research centre for the codominant and additive models were all nonsignificant; : adjusted for age, sex, smoking pack-yrs, research centre and the rate of decline of FEV1 % predicted post-bronchodilator; +: homozygote for the major allele.